AMPLY Discovery is a biotech company harnessing AI and evolution-inspired science to accelerate the discovery of novel biologic drugs. Its proprietary AMPLYfolio AI platform digitises natural genomic diversity and applies machine learning to uncover promising molecules, which are then bio-printed and validated for therapeutic use.
Founded in 2021 as a spin-out from Queen’s University Belfast and part of the QUBIS portfolio, AMPLY Discovery bridges synthetic biology, next-generation sequencing, and AI. The company aims to develop solutions for unmet needs in cancer, antimicrobial resistance, metabolic diseases, and more.
Key milestones:
- Raised $1.75M in seed funding in 2025 led by Twin Path Ventures.
- Secured €1.6M in Innovate UK grants for antimicrobial and oncology research.
- Built by a founding team with 100+ years of drug discovery expertise.